Dr David Meads
- Position: Associate Professor
- Email: D.Meads@leeds.ac.uk
- Phone: +44(0)113 343 0860
- Location: Room 11.63, Level 11, Worsley Building, Clarendon Way
David leads the Economic Evaluation for HTA module on the Health Economics MSc. He is lead economist on several trials, decision modelling and patient preference studies. David is a co-applicant and lead health economist on a number of NIHR- and charity-funded research projects. These include economic evaluations alongside clinical trials, decision-analytic modelling and stated preference studies. He is interested in exploring and improving decision making in healthcare at individual and organisational levels. He is also keen to explore the potential for economics (and behavioural economics) to change behaviour, for example, through the use of financial incentives.
David regularly contributes to the Research Design Service, providing health economics advice to NHS staff developing research proposals.
David's research interests include:
- decision-analytic modelling and Health Technology Assessment
- the valuation of health
- stated preference elicitation and analysis
- behavioural economics and behaviour change.
Current and recent research
Patient preferences for and cost-effectiveness of community intravenous antibiotics (CIVAS).
Dopamine Augmented Rehabilitation in Stroke (DARS). Cost-effectiveness analyses
Pressure Ulcer Programme of Research (PURPOSE). Development of a preference-based measure for use in people with pressure sores.
CRIMSON: A discrete choice experiment to establish the treatment preferences of people with Multiple Sclerosis
I-ASC: A stated preference study to determine the preferences for communication devices in those with communication difficulties
IMPACCT: Improving the Management of Pain from Advanced Cancer in the\n Community – economic model of pain management pathway and patient \npreference elicitation
DCM-EPIC: Economic evaluation alongside a clinical trial of dementia care mapping
TEAMM: Tackling Early Morbidity and Mortality in Myeloma – trial and decision-model based economic evaluation
MUK8: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and bortezomib – trial and decision-model based economic evaluation
TICOPA: Tight Control of Psoriatic Arthritis – Economic evaluation alongside a clinical trial
Module leader for Economic Evaluation for HTA module (MSc Health Economics)
Contributes to the MPH Health Economics module
Introduction to Health Economics for Medical students
Introduction to Health Economics - PGDip Health Services Research \n Short course in decision-analytic modelling
Member of the Health Economics Study Group
Member of the Centre for Decision Research, Leeds University Business School
Member of the Choice Modelling Centre, University of Leeds
Contributor to the Research Design Service for Yorkshire and Humber
Member for the NIHR HTA Elective and Emergency Specialist Care Panel (EESC)
Member of the NICE Technology Appraisal Committee (D)
Member of the Stroke Association funding panel
Research groups and institutes
- Leeds Institute of Health Sciences
- Academic Unit of Health Economics
- Decision Modelling Group
- Health economics